Teva Announces Exclusive Launch of a Generic Version of Reyataz in the U.S.

Teva Pharmaceutical Industries Ltd., announced the exclusive launch of a generic version of Reyataz®1 (atazanavir) capsules in the U.S.

Atazanavir sulfate capsules are a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection for patients 6 years and older weighing at least 15 kg.

“The exclusive launch of our generic version of Reyataz marks our fifth generic product offering for the treatment of HIV-1 infection,” said Brendan O’Grady, Executive Vice President, North America Commercial at Teva. “Antiviral medications continue to be a focus for Teva Generics, and this is an important addition to our portfolio.”

With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Reyataz® had annual sales of approximately $402 million in the U.S., according to IMS data as of October 2017.